Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Triple Negative Breast Neoplasms 1Sarcoma 1Pathologic Complete Response 1Neoplasms 1Lymphoma 1Hemangiosarcoma 1Carcinoma 1Breast Neoplasms 1

Interventions

Doxorubicin 69Radiotherapy 50Ifosfamide 48Gemcitabine 43Cyclophosphamide 36pazopanib 29Filgrastim 28pembrolizumab 26Docetaxel 26Nivolumab 23Surgical Procedures, Operative 21Etoposide 21Cisplatin 21Trabectedin 19Blood Specimen Collection 19Carboplatin 15Radiation 14Magnetic Resonance Spectroscopy 14Vincristine 13Bevacizumab 13anlotinib 12Temozolomide 12Peripheral Blood Stem Cell Transplantation 12Ipilimumab 12liposomal doxorubicin 11apatinib 11Radiosurgery 11Neoadjuvant Therapy 11Melphalan 11Surveys and Questionnaires 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Sarcoma × patritumab × Clear all
NCT01479023 2013-12-20

Evaluation of 64Cu-DOTA-U3-1287 in Subjects With Advanced Solid Tumors

Washington University School of Medicine

Phase 1 Terminated
12 enrolled
LymphoidSarcoma

Carcinoma, Lymphoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡